research News

WINNIPEG — Local medical researchers are optimistic they’ve found the key to unlocking a cure for a rare genetic disorder that affects Hutterite babies. Scientists at the University of Manitoba and the Manitoba Institute of Child Health have discovered that a small change in a gene involved in cell growth,...
Osaka, Japan – Guillain–Barré syndrome (GBS), a rare immune-mediated peripheral neuropathy that can cause permanent disability and even death and be quite severe to manage. In this acute disorder, which typically triggers after a respiratory or gastrointestinal tract infection, the body’s immune system attacks its own peripheral nerves, damaging the...
SEATTLE, WA — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today an update on its ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123 in patients with advanced solid tumors. KVA12123, Kineta’s novel VISTA blocking...
CAMBRIDGE, Mass. — Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, presented the interim safety and efficacy results from its Phase 2 study of KP104 in complement inhibitor-naïve patients with PNH at the 2023 American Society of Hematology (ASH) Annual Meeting held in San...
SEOUL, South Korea — More than two-thirds of patients with hepatocellular carcinoma (HCC), who receive surgical interventions, experience recurrence owing to lack of an established perioperative treatment. Now, researchers from Korea University College of Medicine have performed a meta-analysis to examine the oncological benefits of administering radiotherapy before or after...
Seoul, South Korea – Alzheimer’s disease and Parkinson’s disease, along with stroke, are among the top three neurodegenerative disorders, characterized by the malfunction and progressive degeneration of neurons, the nerve cells. Understanding the mechanisms underlying these neurological disorders and developing therapies requires labeling technologies that can visualize neuronal changes not...
CAMBRIDGE, Mass. — Korro Bio, Inc., a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases, has nominated its first development candidate, KRRO-110, for the potential treatment of AATD. KRRO-110 is a proprietary RNA editing oligonucleotide delivered to liver cells using...